Phase I Clinical Trial To Treat Clostridium Difficile Infection Launches

Each year, roughly 250,000 people in the United States require hospital care for Clostridium difficile (C. difficile) infection and at least 14,000 people die from it, according to the U.S. Centers for Disease Control and Prevention (CDC). As a result, the CDC identified C. difficile as an urgent public health threat in its 2013 report on antibiotic resistance. The National Institute of Allergy and Infectious Diseases (NIAID) has launched an early-stage clinical trial of CRS3123, an investigational oral antibiotic intended to treat C. difficile infection.  CRS3123 (previously known as REP3123) is a narrow-spectrum agent that inhibits C. difficile growth while sparing normal intestinal bacteria. read more

Read the whole article on

More from